Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1957 1
1963 1
1964 3
1965 1
1966 1
1967 1
1980 1
1993 1
1997 1
1998 1
2000 2
2001 6
2002 1
2003 3
2004 4
2007 3
2008 1
2009 3
2010 2
2011 3
2012 4
2013 2
2014 1
2015 4
2016 7
2017 4
2018 7
2019 13
2020 14
2021 4
2022 5
2023 5
2024 4
2025 10

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

113 results

Results by year

Filters applied: . Clear all
Page 1
Showing results for lemonnier j
Search for Lemonier J instead (1 results)
Switch to fulvestrant and palbociclib versus no switch in advanced breast cancer with rising ESR1 mutation during aromatase inhibitor and palbociclib therapy (PADA-1): a randomised, open-label, multicentre, phase 3 trial.
Bidard FC, Hardy-Bessard AC, Dalenc F, Bachelot T, Pierga JY, de la Motte Rouge T, Sabatier R, Dubot C, Frenel JS, Ferrero JM, Ladoire S, Levy C, Mouret-Reynier MA, Lortholary A, Grenier J, Chakiba C, Stefani L, Plaza JE, Clatot F, Teixeira L, D'Hondt V, Vegas H, Derbel O, Garnier-Tixidre C, Canon JL, Pistilli B, André F, Arnould L, Pradines A, Bièche I, Callens C, Lemonnier J, Berger F, Delaloge S; PADA-1 investigators. Bidard FC, et al. Among authors: lemonnier j. Lancet Oncol. 2022 Nov;23(11):1367-1377. doi: 10.1016/S1470-2045(22)00555-1. Epub 2022 Sep 29. Lancet Oncol. 2022. PMID: 36183733 Clinical Trial.
70-Gene Signature as an Aid to Treatment Decisions in Early-Stage Breast Cancer.
Cardoso F, van't Veer LJ, Bogaerts J, Slaets L, Viale G, Delaloge S, Pierga JY, Brain E, Causeret S, DeLorenzi M, Glas AM, Golfinopoulos V, Goulioti T, Knox S, Matos E, Meulemans B, Neijenhuis PA, Nitz U, Passalacqua R, Ravdin P, Rubio IT, Saghatchian M, Smilde TJ, Sotiriou C, Stork L, Straehle C, Thomas G, Thompson AM, van der Hoeven JM, Vuylsteke P, Bernards R, Tryfonidis K, Rutgers E, Piccart M; MINDACT Investigators. Cardoso F, et al. N Engl J Med. 2016 Aug 25;375(8):717-29. doi: 10.1056/NEJMoa1602253. N Engl J Med. 2016. PMID: 27557300 Free article. Clinical Trial.
Anthracycline-containing and taxane-containing chemotherapy for early-stage operable breast cancer: a patient-level meta-analysis of 100 000 women from 86 randomised trials.
Early Breast Cancer Trialists’ Collaborative Group (EBCTCG). Electronic address: bc.overview@ctsu.ox.ac.uk; Early Breast Cancer Trialists’ Collaborative Group (EBCTCG). Early Breast Cancer Trialists’ Collaborative Group (EBCTCG). Electronic address: bc.overview@ctsu.ox.ac.uk, et al. Lancet. 2023 Apr 15;401(10384):1277-1292. doi: 10.1016/S0140-6736(23)00285-4. Lancet. 2023. PMID: 37061269 Free PMC article.
Adjuvant chemotherapy and hormonotherapy versus adjuvant hormonotherapy alone for women aged 70 years and older with high-risk breast cancer based on the genomic grade index (ASTER 70s): a randomised phase 3 trial.
Brain E, Mir O, Bourbouloux E, Rigal O, Ferrero JM, Kirscher S, Allouache D, D'Hondt V, Savoye AM, Durando X, Duhoux FP, Venat-Bouvet L, Blot E, Canon JL, Rollot-Trad F, Bonnefoi H, Roque T, Lemonnier J, Latouche A, Henriques J, Lacroix-Triki M, Vernerey D; GERICO&UCBG/Unicancer. Brain E, et al. Among authors: lemonnier j. Lancet. 2025 Aug 2;406(10502):489-500. doi: 10.1016/S0140-6736(25)00832-3. Lancet. 2025. PMID: 40752909 Clinical Trial.
The tale of TILs in breast cancer: A report from The International Immuno-Oncology Biomarker Working Group.
El Bairi K, Haynes HR, Blackley E, Fineberg S, Shear J, Turner S, de Freitas JR, Sur D, Amendola LC, Gharib M, Kallala A, Arun I, Azmoudeh-Ardalan F, Fujimoto L, Sua LF, Liu SW, Lien HC, Kirtani P, Balancin M, El Attar H, Guleria P, Yang W, Shash E, Chen IC, Bautista V, Do Prado Moura JF, Rapoport BL, Castaneda C, Spengler E, Acosta-Haab G, Frahm I, Sanchez J, Castillo M, Bouchmaa N, Md Zin RR, Shui R, Onyuma T, Yang W, Husain Z, Willard-Gallo K, Coosemans A, Perez EA, Provenzano E, Ericsson PG, Richardet E, Mehrotra R, Sarancone S, Ehinger A, Rimm DL, Bartlett JMS, Viale G, Denkert C, Hida AI, Sotiriou C, Loibl S, Hewitt SM, Badve S, Symmans WF, Kim RS, Pruneri G, Goel S, Francis PA, Inurrigarro G, Yamaguchi R, Garcia-Rivello H, Horlings H, Afqir S, Salgado R, Adams S, Kok M, Dieci MV, Michiels S, Demaria S, Loi S; International Immuno-Oncology Biomarker Working Group. El Bairi K, et al. NPJ Breast Cancer. 2021 Dec 1;7(1):150. doi: 10.1038/s41523-021-00346-1. NPJ Breast Cancer. 2021. PMID: 34853355 Free PMC article. Review.
Deep learning assessment of metastatic relapse risk from digitized breast cancer histological slides.
Garberis I, Gaury V, Saillard C, Drubay D, Elgui K, Schmauch B, Jaeger A, Herpin L, Linhart J, Sapateiro M, Bernigole F, Kamoun A, Filiot A, Tchita O, Dubois R, Auffret M, Guillou L, Bousaid I, Azoulay M, Lemonnier J, Sefta M, Everhard S, Sarrazin A, Reboud JF, Brulport F, Dachary J, Pistilli B, Delaloge S, Courtiol P, André F, Aubert V, Lacroix-Triki M. Garberis I, et al. Among authors: lemonnier j. Nat Commun. 2025 Jul 1;16(1):5876. doi: 10.1038/s41467-025-60824-z. Nat Commun. 2025. PMID: 40593633 Free PMC article.
Pertuzumab Plus Trastuzumab With or Without Chemotherapy Followed by Emtansine in ERBB2-Positive Metastatic Breast Cancer: A Secondary Analysis of a Randomized Clinical Trial.
Huober J, Weder P, Ribi K, Thürlimann B, Thery JC, Li Q, Vanlemmens L, Guiu S, Brain E, Grenier J, Dalenc F, Levy C, Savoye AM, Müller A, Membrez-Antonioli V, Gérard MA, Lemonnier J, Hawle H, Dietrich D, Boven E, Bonnefoi H; Swiss Group for Clinical Cancer Research, Unicancer Breast Group, and Dutch Breast Cancer Research Group. Huober J, et al. Among authors: lemonnier j. JAMA Oncol. 2023 Oct 1;9(10):1381-1389. doi: 10.1001/jamaoncol.2023.2909. JAMA Oncol. 2023. PMID: 37561451 Free PMC article. Clinical Trial.
Darolutamide or capecitabine in triple-negative, androgen receptor-positive, advanced breast cancer (UCBG 3-06 START): a multicentre, non-comparative, randomised, phase 2 trial.
Bonnefoi H, Lerebours F, Pulido M, Arnedos M, Tredan O, Dalenc F, Guiu S, Teixeira L, Mollon D, Levy C, Verret B, Dawood H, Deiana L, Mouret Reynier MA, Augereau P, Canon JL, Huchet N, Guyonneau C, Lemonnier J, MacGrogan G, Gonçalves A, Darbo E, Iggo R. Bonnefoi H, et al. Among authors: lemonnier j. Lancet Oncol. 2025 Mar;26(3):355-366. doi: 10.1016/S1470-2045(24)00737-X. Epub 2025 Feb 17. Lancet Oncol. 2025. PMID: 39978376 Free article. Clinical Trial.
[Breast cancer screening: On our way to the future].
Delaloge S, Bachelot T, Bidard FC, Espie M, Brain E, Bonnefoi H, Gligorov J, Dalenc F, Hardy-Bessard AC, Azria D, Jacquin JP, Lemonnier J, Jacot W, Goncalves A, Coutant C, Ganem G, Petit T, Penault-Llorca F, Debled M, Campone M, Levy C, Coudert B, Lortholary A, Venat-Bouvet L, Grenier J, Bourgeois H, Asselain B, Arvis J, Castro M, Tardivon A, Cox DG, Arveux P, Balleyguier C, André F, Rouzier R; Intergroupe national de recherche sur le cancer du sein Unicancer (UCBG). Delaloge S, et al. Among authors: lemonnier j. Bull Cancer. 2016 Sep;103(9):753-63. doi: 10.1016/j.bulcan.2016.06.005. Epub 2016 Jul 26. Bull Cancer. 2016. PMID: 27473920 Review. French.
113 results